Cargando…

Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment

Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in adults in developed countries, with a global prevalence as high as one billion. The pathogenesis of NAFLD is a multifactorial and multi-step process. Nowadays, a growing body of research suggests the considerable...

Descripción completa

Detalles Bibliográficos
Autores principales: Berk, Klaudia, Bzdega, Wiktor, Konstantynowicz-Nowicka, Karolina, Charytoniuk, Tomasz, Zywno, Hubert, Chabowski, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864168/
https://www.ncbi.nlm.nih.gov/pubmed/33498537
http://dx.doi.org/10.3390/jcm10030393
_version_ 1783647614064918528
author Berk, Klaudia
Bzdega, Wiktor
Konstantynowicz-Nowicka, Karolina
Charytoniuk, Tomasz
Zywno, Hubert
Chabowski, Adrian
author_facet Berk, Klaudia
Bzdega, Wiktor
Konstantynowicz-Nowicka, Karolina
Charytoniuk, Tomasz
Zywno, Hubert
Chabowski, Adrian
author_sort Berk, Klaudia
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in adults in developed countries, with a global prevalence as high as one billion. The pathogenesis of NAFLD is a multifactorial and multi-step process. Nowadays, a growing body of research suggests the considerable role of the endocannabinoid system (ECS) as a complex cell-signaling system in NAFLD development. Although increased endocannabinoid tone in the liver highly contributes to NAFLD development, the complex effects and impacts of plant-derived cannabinoids in the aspect of NAFLD pathophysiology are yet not fully understood, and effective medications are still in demand. In our review, we present the latest reports describing the role of ECS in NAFLD, focusing primarily on two types of cannabinoid receptors. Moreover, we sum up the recent literature on the clinical use of natural cannabinoids in NAFLD treatment. This review is useful for understanding the importance of ECS in NAFLD development, and it also provides the basis for more extensive clinical phytocannabinoids testing in patients suffering from NAFLD.
format Online
Article
Text
id pubmed-7864168
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78641682021-02-06 Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment Berk, Klaudia Bzdega, Wiktor Konstantynowicz-Nowicka, Karolina Charytoniuk, Tomasz Zywno, Hubert Chabowski, Adrian J Clin Med Review Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in adults in developed countries, with a global prevalence as high as one billion. The pathogenesis of NAFLD is a multifactorial and multi-step process. Nowadays, a growing body of research suggests the considerable role of the endocannabinoid system (ECS) as a complex cell-signaling system in NAFLD development. Although increased endocannabinoid tone in the liver highly contributes to NAFLD development, the complex effects and impacts of plant-derived cannabinoids in the aspect of NAFLD pathophysiology are yet not fully understood, and effective medications are still in demand. In our review, we present the latest reports describing the role of ECS in NAFLD, focusing primarily on two types of cannabinoid receptors. Moreover, we sum up the recent literature on the clinical use of natural cannabinoids in NAFLD treatment. This review is useful for understanding the importance of ECS in NAFLD development, and it also provides the basis for more extensive clinical phytocannabinoids testing in patients suffering from NAFLD. MDPI 2021-01-20 /pmc/articles/PMC7864168/ /pubmed/33498537 http://dx.doi.org/10.3390/jcm10030393 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Berk, Klaudia
Bzdega, Wiktor
Konstantynowicz-Nowicka, Karolina
Charytoniuk, Tomasz
Zywno, Hubert
Chabowski, Adrian
Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
title Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
title_full Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
title_fullStr Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
title_full_unstemmed Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
title_short Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
title_sort phytocannabinoids—a green approach toward non-alcoholic fatty liver disease treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864168/
https://www.ncbi.nlm.nih.gov/pubmed/33498537
http://dx.doi.org/10.3390/jcm10030393
work_keys_str_mv AT berkklaudia phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment
AT bzdegawiktor phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment
AT konstantynowicznowickakarolina phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment
AT charytoniuktomasz phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment
AT zywnohubert phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment
AT chabowskiadrian phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment